Voices
Fatima Cardoso
Fatima Cardoso/myoncologia.pt

600 mg vs 400 mg Ribociclib in HR+/ERBB2: Advanced Breast Cancer – JAMA Oncology

JAMA Oncology shared a post on LinkedIn:

“A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events, supporting 600 mg as the standard dose with reduction to manage toxicity.”

Title: 600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ERBB2-Negative Advanced Breast Cancer

Authors: Fatima Cardoso, William Jacot, Sherko Kuemmel, Sudeep Gupta, Felipe Cruz, Rama Balaraman, Ana Ferreira, Tytti Ahola, Yana Chapko, Lyudmila Zhukova, Wendy Chiang, Zheng Li, Yan Ji, Nadia Kaakiou, Natalia Bolotova, Joseph Sparano

Read the Full Article.

JAMA Oncology

More from JAMA Oncology on OncoDaily.

Ana Ferreira Breast Cancer cancer Fatima Cardoso Felipe Cruz JAMA Oncology Joseph Sparano Lyudmila Zhukova Nadia Kaakiou Natalia Bolotova OncoDaily Oncology Rama Balaraman Sherko Küemmel Sudeep Gupta Tytti Ahola Wendy Chiang William Jacot Yan Ji Yana Chapko Zheng Li